SCHEMBL2724262

SCHEMBL2724262

OCc1cncc(N2CCNCC2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.58
HTR2A P28223 4/20 0.58
HTR1A P08908 3/20 0.58
ALDH1A1 P00352 3/20 0.58
KDM4E B2RXH2 2/20 0.58
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 2/20 0.58
HSD17B10 Q99714 2/20 0.58
MEN1 O00255 1/20 0.58
CYP2C9 P11712 1/20 0.58
HPGD P15428 1/20 0.58
CYP2C19 P33261 1/20 0.58
KMT2A Q03164 1/20 0.58
PIM2 Q9P1W9 4/20 0.50
PIM1 P11309 3/20 0.50
PIM3 Q86V86 3/20 0.50
HTR2B P41595 3/20 0.42
ADRB2 P07550 1/20 0.42
HTR3A P46098 3/20 0.41
ADRB1 P08588 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919280 0.85 HTR2C (0.60) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL24324093 0.83 PDE10A (0.46) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL24922389 0.80 ALDH1A1 (0.40) ALDH1A1KDM4ECYP1A2HSD17B10MEN1
SCHEMBL3267269 0.77 TAAR1 (0.54) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL25189276 0.77 HTR3E (0.58) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL13039373 0.74 HTR2C (0.64) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL19581644 0.74 HTR2C (0.64) HTR2CHTR2AHTR1AALDH1A1KDM4E
Mk-212 SCHEMBL29389957 0.74 HTR2A (1.00) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL6014714 0.74 HTR2C (0.64) HTR2CHTR2AHTR1AALDH1A1KDM4E
SCHEMBL1026934 0.74 HTR2C (0.64) HTR2CHTR2AHTR1AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225583-A1 SUBSTITUTED AMINO-TRIAZOLYL PDE10 INHIBITORS MERCK SHARP & DOHME CORP. 2013-08-29 US disclosed
EP-2629616-A2 SUBSTITUTED AMINO-TRIAZOLYL PDE10 INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-08-28 EP disclosed
WO-2012054366-A2 SUBSTITUTED AMINO-TRIAZOLYL PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225583-A1 SUBSTITUTED AMINO-TRIAZOLYL PDE10 INHIBITORS PDE10A, PDE12, PDE4A HTR2C 136/4885HTR2A 124/4885HTR1A 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.